DOS/A
LIVE
0001772028
XXXXXXXX
false
false
false
Scopus BioPharma Inc.
DE
2017
0001772028
2834
82-1248020
2
0
420 LEXINGTON AVENUE
SUITE 300
NEW YORK
NY
10170
2124792513
Mark Wishner
Other
869420.00
0.00
0.00
2250.00
1478085.00
378983.00
0.00
378983.00
1099102.00
1478085.00
0.00
0.00
0.00
-929519.00
-0.08
-0.08
Citrin Cooperman & Company, LLP
common stock
12509024
809171101
N/A
options and warrants
1050000
000000000
N/A
private placement warrants
1441483
000000000
N/A
N/A
0
000000000
N/A
N/A
0
000000000
N/A
true
true
false
Tier2
Audited
Equity (common or preferred stock)
Option, warrant or other right to acquire another security
Security to be acquired upon exercise of option, warrant or other right to acquire security
N
N
Y
Y
N
N
200000
12509024
0.00
0.00
0.00
0.00
0.00
Citrin Cooperman & Company, LLP
0.00
Kaufman & Associates, LLC and Greenberg Traurig, LLP
0.00
true
false
CA
CO
CT
DC
FL
IL
MA
NJ
NY
PA
TX
UT
VA
false
Scopus Biopharma Inc.
units comprised of shares of common stock and warrants
150169
0
$450,507 in connection with the sale of each unit for $3.00 per unit.
Scopus Biopharma Inc.
units comprised of shares of common stock and warrants
610361
0
$915,541.50 of gross proceeds in connection with the sale of each unit for $1.50 per unit.
Scopus Biopharma Inc.
Options to purchase common stock
425000
0
$0.00 in connection with 425,000 options granted under Scopus Biopharma Inc.'s 2018 Equity Incentive Plan.
Scopus Biopharma Inc.
Common stock
858855
0
$858,855 in connection with the exercise of warrants, each exercisable for one share of common stock at an exercise price of $1.00.
Private placements of units of common stock and warrants were conducted under Securities Act Rule 506(b) without general solicitation. Private placements of options to employees were conducted under Securities Act Rule 701.